Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Viruses?00:50

What are Viruses?

109.8K
Overview
109.8K
Introduction to Virus01:28

Introduction to Virus

2.9K
Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
2.9K
Viral Replication: Lytic Cycle01:20

Viral Replication: Lytic Cycle

3.0K
Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...
3.0K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.5K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.5K
Upstream Processing01:27

Upstream Processing

102
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
102
Vaccine Production01:23

Vaccine Production

152
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
152

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering Viral Surface Antigens to Improve Display on Virus-like Particle (VLP) Vaccine Prototypes.

Biotech (Basel (Switzerland))·2026
Same author

Process Analytical Technology-Integrated FT-IR and Raman Spectroscopies for Efficient Reactive Liquid-Liquid Extraction Processing in Lithium Recycling.

ACS omega·2025
Same author

Digital Twin for the Production of hMSC-Derived Extracellular Vesicles for Applications in Cell and Gene Therapy toward Autonomous Operation.

ACS omega·2025
Same author

Advanced Freeze-Drying Modeling: Validation of a Sorption-Sublimation Model.

ACS omega·2025
Same author

Development of Lentiviral Packaging Cells and Scale Up of Production to Meet the Growing Demand in Cell and Gene Therapy.

Current gene therapy·2025
Same author

Development of HIV-1 vectors pseudotyped with envelope proteins of other retroviruses.

Virology·2024

Related Experiment Video

Updated: May 6, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K

Platform Process for an Autonomous Production of Virus-like Particles.

Simon Baukmann1, Alina Hengelbrock1, Kristina Katsoutas2

  • 1Institute for Separation and Process Technology, Clausthal University of Technology, 38678 Clausthal-Zellerfeld, Germany.

ACS Omega
|February 10, 2025
PubMed
Summary
This summary is machine-generated.

This study presents a streamlined platform process for producing virus-like particles (VLPs) using advanced process analytical technology (PAT). This approach enhances VLP production efficiency and control, paving the way for autonomous manufacturing.

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.2K

Related Experiment Videos

Last Updated: May 6, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

58.9K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.2K

Area of Science:

  • Biotechnology and Bioprocessing
  • Vaccine Development and Manufacturing
  • Process Analytical Technology (PAT)

Background:

  • Virus-like particles (VLPs) are crucial for vaccine and therapeutic development but face production challenges.
  • Existing VLP production methods involve long timelines and complex purification processes.

Purpose of the Study:

  • To introduce a robust platform process for VLP production and purification.
  • To integrate Process Analytical Technology (PAT) for enhanced process control and efficiency.
  • To develop a stable, high-yield cell line for VLP manufacturing.

Main Methods:

  • Fed-batch cultivation and purification using membrane technology and anion-exchange chromatography.
  • Development of a novel HEK293F cell line with the Sleeping Beauty transposon vector.
  • Implementation of in situ microscopy (ISM), Raman, FTIR, and DAD spectroscopies for real-time monitoring.
  • Utilizing FTIR for buffer composition analysis and diafiltration control.

Main Results:

  • A 3.6-fold increase in productivity was achieved with the novel HEK293F cell line compared to a PiggyBac-based line.
  • ISM accurately predicted viable cell density in mammalian cell cultures.
  • Spectroscopic methods (Raman, FTIR, DAD) successfully predicted metabolites and impurities.
  • FTIR enabled robust process control for buffer exchange during diafiltration.

Conclusions:

  • The developed platform process, enhanced by PAT, significantly improves VLP production efficiency and control.
  • Real-time data from PAT enables predictive control strategies, potentially leading to autonomous VLP manufacturing.
  • The novel cell line and integrated PAT approach offer a scalable and robust solution for VLP production.